SCHEDULE 13G/A: BlackRock Reduces Stake in Pliant Therapeutics to 3.4%
Ownership Disclosure
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a reduced beneficial ownership of 3.4% in Pliant Therapeutics Inc.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in PLIANT THERAPEUTICS INC.
- As of June 30, 2025, BlackRock, Inc. beneficially owned 2,104,574 shares of Pliant Therapeutics Inc. common stock.
- This represents 3.4% of the total class of securities outstanding.
- BlackRock, Inc. holds sole voting power over 2,086,513 shares and sole dispositive power over 2,104,574 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative. While BlackRock maintains a significant stake, the reduction in beneficial ownership to 3.4% from a likely higher previous position could be perceived as a negative signal by the market.
Positives
- BlackRock, Inc., a prominent institutional investor, maintains a significant beneficial ownership stake in Pliant Therapeutics Inc., indicating continued institutional interest.
- The filing confirms BlackRock's passive investment intent, stating the shares are held in the ordinary course of business and not for control purposes.
Negatives
- BlackRock, Inc.'s beneficial ownership has decreased to 3.4% of Pliant Therapeutics Inc.'s common stock, which is below the 5% threshold typically associated with initial Schedule 13G filings, suggesting a reduction in their overall stake.
Risks
- The document does not detail specific risks related to Pliant Therapeutics Inc.'s operations or financial health. It only states that BlackRock's holdings are not for the purpose of changing or influencing control of the issuer.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Pliant Therapeutics Inc.'s future performance or strategic direction.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
Pliant Therapeutics Inc. operates in the biotechnology or pharmaceutical industry. BlackRock, Inc.'s filing reflects routine institutional investment activity and disclosure within the broader financial markets, indicating continued institutional interest in the biotech sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization Update | BlackRock, Inc. updated its Power of Attorney, effective January 21, 2025, authorizing specific individuals to execute documents related to ownership or control-person reporting requirements for various regulatory bodies, including the SEC. This new power of attorney revokes a previous one dated April 30, 2023. | January 21, 2025 | Streamlines BlackRock's compliance with regulatory reporting obligations by clearly designating authorized signatories for SEC and other governmental filings. |
Stakeholder Impact
- Shareholders: The disclosure of BlackRock's reduced stake may influence investor sentiment and potentially the stock price.
- Management: Awareness of significant institutional ownership changes can inform investor relations strategies.
Next Steps
- No specific future actions or milestones for Pliant Therapeutics Inc. are mentioned in this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| January 21, 2025 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| June 30, 2025 | Date of event which requires the filing of this statement (reporting period end). |
| July 17, 2025 | Date the Schedule 13G Amendment No. 1 was signed by BlackRock, Inc. |
Keywords
Pliant Therapeutics, BlackRock, Institutional Ownership, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.